Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and a Waiver under 18 U.S.C. §208(b)(3)

John Bradley, M.D.

Committee: Anti-Infective Drugs Advisory Committee

Meeting Date: March 6, 2006

I acknowledge that contingent upon public disclosure of the financial interest listed below, related to New Drug Application (NDA) 21-572/S-008, Cubicin (daptomycin for injection 500 mg/vial), manufactured for Cubist Pharmaceuticals by Integrated Commercialization Solutions, for the proposed indication for the treatment of Staphylococcus aureus bacteremia, including those with known or suspected endocarditis caused by methicillin-susceptible and methicillin-resistant strains, I am eligible to receive a waiver under 18 U.S.C. §208 (b)(3).

Type of Interest	Nature	Magnitude
Unrelated Consulting	Competitor	Less than \$10,001 per year.

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of this interest the waiver is not valid.

//S// Signature of SGE 1/27/06

Date